menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

IUGNF / Imugene secures FDA approval for two clinical trials of promising oncology drug candidates

Imugene secures FDA approval for two clinical trials of promising oncology drug candidates
Imugene Limited (ASX:IMU, OTC:IUGNF) has obtained US Food and Drug Administration (FDA) consent for clinical trials for two of its oncology treatments, securing Investigational New Drug (IND) approval to initiate a Phase I clinical trial for oncolytic virotherapy candidate VAXINIA (CF33-hNIS, HOV2) and a Phase II trial of immunotherapy candidate HER-Vaxx. The FDA approval of the INDs were received on December 10, 2021, and allows Imugene to start patient recruitment and dosing for the two trials. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Imugene

Secures

Approval

Clinical

Trials

Promising

Oncology

Candidates

Stock

IUGNF

Posted: Dec 12 2021, 19:40
Author Name: Proactive Investors
Views: 110830

IUGNF News  

Imugene appoints experienced life sciences CFO in newly created in-house role

By Proactive Investors
July 17, 2022

Imugene appoints experienced life sciences CFO in newly created in-house role

Imugene Ltd (ASX:IMU, OTC:IUGNF) (Imugene Ltd (ASX:IMU, OTC:IUGNF), Imugene Ltd (ASX:IMU, OTC:IUGNF)) has signed up a chief financial officer (CFO) in more_horizontal

Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer

By Proactive Investors
January 31, 2022

Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer

Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed Dr Steven Cha as its chief medical officer (CMO) and a member of its executive management team. Dr Cha more_horizontal

Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer

By Proactive Investors
January 31, 2022

Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer

Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed Dr Steven Cha as its chief medical officer (CMO) and a member of its executive management team. Dr Cha more_horizontal

Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer

By Proactive Investors
January 31, 2022

Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer

Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed Dr Steven Cha as its chief medical officer (CMO) and a member of its executive management team. Dr Cha more_horizontal

Imugene secures Japanese grant notice for Oncolytic Virotherapy CF33 Patent

By Proactive Investors
January 30, 2022

Imugene secures Japanese grant notice for Oncolytic Virotherapy CF33 Patent

Imugene Ltd (ASX:IMU, OTC:IUGNF) has received a notice of grant from the Japanese Patent Office for Patent Application number 2019-507161 which protec more_horizontal

Imugene secures Japanese grant notice for Oncolytic Virotherapy CF33 Patent

By Proactive Investors
January 30, 2022

Imugene secures Japanese grant notice for Oncolytic Virotherapy CF33 Patent

Imugene Ltd (ASX:IMU, OTC:IUGNF) has received a notice of grant from the Japanese Patent Office for Patent Application number 2019-507161 which protec more_horizontal

Imugene secures Japanese grant notice for Oncolytic Virotherapy CF33 Patent

By Proactive Investors
January 30, 2022

Imugene secures Japanese grant notice for Oncolytic Virotherapy CF33 Patent

Imugene Ltd (ASX:IMU, OTC:IUGNF) has received a notice of grant from the Japanese Patent Office for Patent Application number 2019-507161 which protec more_horizontal

Imugene granted patent for gastric cancer therapy in major oncology market

By Proactive Investors
January 27, 2022

Imugene granted patent for gastric cancer therapy in major oncology market

Imugene Ltd (ASX:IMU, OTC:IUGNF) has opened the doors to a large and lucrative market for immuno-oncology by securing a Notice of Grant from the Euro more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: